DENTSPLY SIRONA Inc. (NASDAQ:XRAY) Receives Average Rating of “Hold” from Analysts

DENTSPLY SIRONA Inc. (NASDAQ:XRAY) has earned an average recommendation of “Hold” from the fifteen ratings firms that are covering the stock, MarketBeat.com reports. Three investment analysts have rated the stock with a sell recommendation, nine have given a hold recommendation and three have issued a buy recommendation on the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $13.5385.

Several equities research analysts recently issued reports on XRAY shares. Piper Sandler upped their price target on DENTSPLY SIRONA from $13.00 to $14.00 and gave the company a “neutral” rating in a research report on Wednesday, July 29th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of DENTSPLY SIRONA in a report on Monday, August 3rd. Barrington Research set a $15.00 target price on shares of DENTSPLY SIRONA in a research note on Monday, August 10th. Barclays increased their target price on shares of DENTSPLY SIRONA from $9.00 to $11.00 and gave the stock an “underweight” rating in a report on Monday, August 24th. Finally, BMO Capital Markets restated a “market perform” rating and issued a $13.00 price target on shares of DENTSPLY SIRONA in a research report on Friday, August 7th.

DENTSPLY SIRONA Price Performance

Shares of DENTSPLY SIRONA stock opened at $11.38 on Wednesday. The business has a 50-day moving average price of $12.16 and a 200 day moving average price of $11.66. DENTSPLY SIRONA has a fifty-two week low of $9.40 and a fifty-two week high of $14.86. The firm has a market cap of $2.27 billion, a P/E ratio of -4.14, a P/E/G ratio of 1.45 and a beta of 0.84. The company has a quick ratio of 1.07, a current ratio of 1.63 and a debt-to-equity ratio of 1.48.

DENTSPLY SIRONA (NASDAQ:XRAY) last released its earnings results on Thursday, August 6th. The medical instruments supplier reported $0.52 EPS for the quarter, topping analysts’ consensus estimates of $0.35 by $0.17. The company had revenue of $898.00 million for the quarter, compared to the consensus estimate of $889.93 million. DENTSPLY SIRONA had a positive return on equity of 20.84% and a negative net margin of 14.99%.DENTSPLY SIRONA’s quarterly revenue was down 4.1% compared to the same quarter last year. During the same quarter last year, the business posted $0.52 EPS. DENTSPLY SIRONA has set its FY 2026 guidance at 1.400-1.500 EPS. On average, sell-side analysts forecast that DENTSPLY SIRONA will post 1.4 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, Director Michael J. Barber bought 15,175 shares of the stock in a transaction dated Thursday, June 11th. The stock was bought at an average cost of $9.88 per share, with a total value of $149,929.00. Following the completion of the acquisition, the director owned 55,943 shares of the company’s stock, valued at $552,716.84. This trade represents a 37.22% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Brian T. Gladden purchased 9,985 shares of the company’s stock in a transaction dated Monday, June 15th. The shares were bought at an average price of $10.02 per share, for a total transaction of $100,049.70. Following the completion of the transaction, the director directly owned 61,849 shares in the company, valued at approximately $619,726.98. This trade represents a 19.25% increase in their position. The SEC filing for this purchase provides additional information. Insiders have acquired a total of 35,160 shares of company stock worth $351,179 over the last quarter. 0.46% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in XRAY. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new stake in DENTSPLY SIRONA in the first quarter valued at $26,000. Eurizon Capital SGR S.p.A. bought a new position in shares of DENTSPLY SIRONA during the fourth quarter worth about $26,000. Caitong International Asset Management Co. Ltd grew its position in shares of DENTSPLY SIRONA by 337.9% during the third quarter. Caitong International Asset Management Co. Ltd now owns 2,750 shares of the medical instruments supplier’s stock worth $35,000 after acquiring an additional 2,122 shares during the last quarter. Nykredit A S acquired a new stake in shares of DENTSPLY SIRONA in the 2nd quarter worth about $38,000. Finally, Farther Finance Advisors LLC lifted its position in DENTSPLY SIRONA by 119.1% in the 4th quarter. Farther Finance Advisors LLC now owns 3,773 shares of the medical instruments supplier’s stock valued at $43,000 after purchasing an additional 2,051 shares during the last quarter. 95.70% of the stock is currently owned by institutional investors.

DENTSPLY SIRONA Company Profile

Dentsply Sirona Inc (NASDAQ: XRAY) is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.

The company’s product portfolio spans preventive, restorative, orthodontic, endodontic and surgical care.